Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
Zevra Therapeutics revealed that the US Food and Drug Administration (FDA) has indicated it will convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee (GeMDAC) on August 2, 2024, to review the New Drug Application (NDA) for arimoclomol. 15 July 2024
A US Food and Drug Administration advisory panel on Wednesday backed the expanded use of Alnylam Pharmaceuticals' gene silencing drug to treat a type of heart disease associated with a rare organ-damaging disorder. 14 September 2023
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued final draft guidance that recommends US pharma giant Pfizer’s Vydura (rimegepant) as an option for the acute treatment of migraine. 14 September 2023
US genomics-based drug discovery company Exelixis has entered into an exclusive license agreement with Sino-American firm Insilico Medicine for global rights to develop and commercialize the latter’s ISM3091. 13 September 2023
Oral phenylephrine has for years generated major revenues as an over-the-counter decongestant, but a meeting of the US Food and Drug Administration’s scientific experts has thrown a wrench in the works. 13 September 2023
The European Medicines Agency (EMA) has validated Japanese pharma major Astellas Pharma’s Type II variation for Xtandi (enzalutamide) for the treatment of patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC). 13 September 2023
With the European Commission Decision Reliance Procedure (ECDRP) due to come to an end on December 31, 2023 - subject to consultation - the UK’s Medicines and Healthcare Regulatory Agency (MHRA) will launch a new International Recognition Procedure (IRP) from January 1, 2024. 12 September 2023
A new agreement is poised to accelerate antibiotic access for tens of thousands of patients in regions with the highest rates of antimicrobial resistance (AMR). 12 September 2023
US clinical-stage liver disease drug developer Madrigal Pharmaceuticals today announced that Bill Sibold has succeeded Dr Paul Friedman as the firm’s chief executive and joined Madrigal’s board of directors. 11 September 2023
Florida, USA-based biotech Veru has expressed its confidence in breast cancer candidate enobosarm, citing data from a discontinued Phase III trial. 11 September 2023
Around 180,000 people in England and Wales with difficult to manage type 2 diabetes could benefit from a new treatment option recommended by the National Institute for Health and Care Excellence (NICE. 11 September 2023
The Belgian pharmaceutical industry has responded to reports of medicine shortages, with local media attributing the blame in some cases to the actions of pharmaceutical companies. 11 September 2023
Shares of US drug developer Crinetics Pharmaceuticals shot up more than 66%% to $26.60 pre-market, after its experimental treatment for a rare hormonal disorder not only succeeded, but performed better than Wall Street expectations. 11 September 2023
Japan’s Ministry of Health, Labor and Welfare (MHLW) has accepted for review a new drug application (NDA) for momelotinib, filed by UK pharma major GSK. 11 September 2023
Multi-stakeholder group consisting of 32 European patient organizations, medical associations, research organizations, data collaborations and industry associations consider EHDA opt-out. 11 September 2023
Boston, USA-based Glyscend Therapeutics, which is developing a revolutionary approach to treating type 2 diabetes, has appointment of Sapan Shah as chief executive (CEO). 8 September 2023
US biopharma CymaBay Therapeutics traded up as much as 21% to $16.73 yesterday, as the company released encouraging trial results for its primary biliary cholangitis (PBC) candidate after earlier disappointments. 8 September 2023
UK cancer and infectious disease drug developer Scancell Holdings has appointed Dr Mandeep Sehmi as head of business development, effective immediately. 8 September 2023
After years of uncertainty stemming from the UK’s departure from the European Union (EU), Prime Minister Rishi Sunak has confirmed that, from Thursday onwards, British scientists can apply once again for grants from the £85 billion ($106 billion) Horizon program. 7 September 2023